Drug interactions
Cyclophosphamide + Tisagenlecleucel
Severity: Moderate
Cyclophosphamide and Tisagenlecleucel: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Cyclophosphamide is part of the lymphodepleting regimen before tisagenlecleucel, so the pairing is intended in that setting. Unplanned or additional cyclophosphamide adds to immunosuppression and infection risk and may affect CAR-T expansion.
What this interaction means in plain words
Cyclophosphamide and Tisagenlecleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Cyclophosphamide belongs to Oncology; Tisagenlecleucel belongs to Oncology.
Why it happens
Additive immunosuppression and lymphodepletion that can affect CAR-T cell expansion and persistence.
What to do
Give cyclophosphamide only as part of the labeled lymphodepletion and avoid extra doses around infusion. Monitor for infection and cytopenias.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Cyclophosphamide and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Cyclophosphamide
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Cyclophosphamide with Tisagenlecleucel?
MediHelp rates the interaction as moderate. Cyclophosphamide and Tisagenlecleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Cyclophosphamide is part of the lymphodepleting regimen before tisagenlecleucel, so the pairing is intended in that setting. Unplanned or additional cyclophosphamide adds to immunosuppression and infection risk and may affect CAR-T expansion.
How serious is the interaction between Cyclophosphamide and Tisagenlecleucel?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Give cyclophosphamide only as part of the labeled lymphodepletion and avoid extra doses around infusion. Monitor for infection and cytopenias.
What other medicines interact with Cyclophosphamide?
MediHelp also lists interactions of Cyclophosphamide with, for example, Adenovirus types 4 and 7 live, Belatacept, Bendamustine. The full list is on the Cyclophosphamide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
